Mary Ann Hardwicke - Concepedia

Author

Mary Ann Hardwicke

GlaxoSmithKline (United States)

Also Known As

Hardwicke, Mary, M A Hardwicke, M.A. Hardwicke, Mary Ann A. Hardwicke, Mary Ann Hardwicke, Mary Ann Hardwicke

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)University of California, Irvine South College Research Triangle Park Foundation Lawrence Berkeley National Laboratory

About

Mary Ann Hardwicke is an author at GlaxoSmithKline (United States) specializing in medicine, cell biology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2K
2	Natural Sciences	12	12	631
3	Biochemistry	6	6	359
4	Health Sciences	1	1	103
5	Biomolecular Engineering	1	1	103

Mary Ann Hardwicke

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Subtype and pathway specific responses to anticancer compounds in breast cancer Laura M. Heiser, Anguraj Sadanandam, Wen‐Lin Kuo, Proceedings of the National Academy of Sciences Drug TargetBreast OncologyChemoprevention StrategyTherapeutic CompoundsCancer Biology	2011	501
Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression Irene L. Smith, Mary Ann Hardwicke, Rozanne M. Sandri-Goldin Virology Transcriptional RegulationViral ReplicationEarly Protein Icp27Viral PathogenesisImmunology	1992	281
The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection Mary Ann Hardwicke, Rozanne M. Sandri-Goldin Journal of Virology Viral ReplicationIcp27 Viral MutantsImmunologyViral PathogenesisViral Structural Protein	1994	189
Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers Wenle Xia, John Bisi, Jay C. Strum, Cancer Research	2006	151
The C-terminal repressor region of herpes simplex virus type 1 ICP27 is required for the redistribution of small nuclear ribonucleoprotein particles and splicing factor SC35; however, these alterations are not sufficient to inhibit host cell splicing Rozanne M. Sandri-Goldin, M K Hibbard, Mary Ann Hardwicke Journal of Virology Viral ReplicationImmediate-early Protein Icp27ImmunologyMolecular BiologyViral Structural Protein	1995	131
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models Mary Ann Hardwicke, Catherine A. Oleykowski, Ramona Plant, Molecular Cancer Therapeutics Aurora ACell DeathCancer BiologyTissue Culture CellsTumor Biology	2009	110
Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase Nicholas D. Adams, Jerry L. Adams, Joelle L. Burgess, Journal of Medicinal Chemistry Aurora B/c KinaseChemoprevention StrategyMolecular BiologyTumor BiologyMolecular Pharmacology	2010	108
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site Mary Ann Hardwicke, Alan R. Rendina, Shawn P. Williams, Nature Chemical Biology Metabolic SyndromeLipid SynthesisBiochemistryβ-Ketoacyl ReductaseMetabolic Regulation	2014	103
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors Lin Hong, Jin Zeng, Ren Xie, ACS Medicinal Chemistry Letters	2015	84
The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule Mary Ann Hardwicke, P Vaughan, Rose E. Sekulovich, Journal of Virology Viral ReplicationImmunologyMolecular BiologyIcp27 GeneViral Structural Protein	1989	82

Page 1